ClinicalTrials.gg
RecruitingNCT06314594Updated Oct 27, 2026

Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS

An interventional study of Routine Guideline-Based Conservative Care and Clinician-Supervised, Platform-Assisted Conservative Management in Adolescent Idiopathic Scoliosis (AIS), sponsored by Hangzhou Medical College. Recruiting at 1 site in China. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Hangzhou Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 27, 2026Start date movedPrimary completion moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
12 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Scoliosis with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Scoliosis · China.

Planned enrollment
22nd of 37
76 · median 100
Started
2025
with 4 others
No phase
31 of 55
14 open now
Primary completion
2026-11
later than 11 of 25 live
Registered
33rd of 55
by date

Among the 55 studies in Scoliosis with a site in China, this one is the 22nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 33rd registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

22 of the 55 studies in Scoliosis with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 12 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Scoliosis with a site in China, or all of them as a file.
02

Study summary

Adolescent idiopathic scoliosis (AIS) brings substantial physical and psychological burden to affected teenagers, and current conservative follow-up management is fragmented under routine clinical settings. This single-center, superiority, parallel-group, 1:1 randomized controlled trial with assessor-blinded outcome evaluation will compare a clinician-supervised, platform-supported collaborative care pathway with routine guideline-based conservative care in 76 adolescents with mild-to-moderate AIS. Participants will be assessed at baseline, 4-month (primary endpoint), 8-month, and 12-month follow-up. The primary outcome is the change in Cobb angle from baseline to 4 months. Secondary outcomes include treatment adherence, mental-health status, medical expenditure, participant and guardian satisfaction, and safety outcomes. The primary analysis will follow the intention-to-treat principle. The first participant was enrolled on 26 March 2025; to date, 35 of the target 76 participants have been recruited.

Read the detailed description

Adolescent idiopathic scoliosis (AIS) is the most prevalent form of scoliosis, affecting 2% to 4% of the global teenage population and imposing substantial physical and psychological burdens. In China, a 2024 systematic review and modelling study estimated that the prevalence of idiopathic scoliosis among children aged 5-18 years was 0.79% in 2020, corresponding to approximately 1.81 million affected children. Current conservative follow-up management for adolescents with AIS remains fragmented under routine clinical settings, with limited integration across home, school, and hospital care.

This trial evaluates the clinical effectiveness of a comprehensive digital health management platform that supports a clinician-supervised, home-school-hospital collaborative care pathway for the conservative management of adolescents with established AIS. The platform integrates nine functional modules: electronic health records, disease risk early warning, health intervention and promotion, standardized health education, follow-up management, system administration, data quality control and review, data analysis and utilization, and visual data display. It serves solely as a clinical decision-support tool; all platform-generated recommendations must be manually reviewed, adjusted, and formally approved by licensed clinicians before being shared with patients.

The trial is a single-center, superiority, parallel-group, 1:1 randomized controlled trial with assessor-blinded outcome evaluation. A total of 76 eligible adolescents with mild-to-moderate AIS (Cobb angle 10 degrees to less than 45 degrees, aged 12-16 years) will be randomly allocated to either the control group receiving routine guideline-based conservative care or the intervention group receiving clinician-supervised, platform-supported collaborative care. Both groups have access to the same guideline-based conservative treatment options, including observation, physiotherapeutic scoliosis-specific exercises (PSSE), specialized inpatient rehabilitation, and bracing, in accordance with the 2016 SOSORT guidelines. Randomization will be stratified by baseline Cobb-angle strata (10-24 degrees vs 25-44 degrees) and skeletal maturity (Risser 0-2 vs Risser 3-5).

Outcome assessments will be conducted at baseline and at 4, 8, and 12 months. The primary outcome is the change in Cobb angle from baseline to the 4-month endpoint. Secondary outcomes include treatment adherence, mental-health status (assessed with the Hamilton Depression Rating Scale-17), cumulative direct out-of-pocket medical expenditure, participant and guardian satisfaction, and safety outcomes. The primary analysis will follow the intention-to-treat principle and will use analysis of covariance adjusting for baseline Cobb angle. Sensitivity analyses include per-protocol analysis, multiple imputation under missing-at-random assumptions, complete-case analysis, and pattern-mixture-model-based analyses for missing-not-at-random scenarios.

The first participant was enrolled on 26 March 2025. To date, 35 of the target 76 participants have been recruited. No primary endpoint outcome data have been unlocked or analysed at the time of this protocol version.

03

Conditions studied

  • Adolescent Idiopathic Scoliosis (AIS)

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of mild-to-moderate Adolescent Idiopathic Scoliosis (AIS), with a Cobb angle of 10 degrees or greater and less than 45 degrees.
  2. Age 12 to 16 years, targeting adolescents in the active pubertal growth phase, in whom conservative management (PSSE and bracing) is clinically prioritized.
  3. Sufficient cognitive and communicative ability to understand the study procedures and use the platform.
  4. Voluntary participation confirmed by signed guardian and adolescent participant assent.
  5. Participants with prior conservative treatment (PSSE or bracing) are eligible provided the treatment regimen has been stable for at least 3 months prior to baseline assessment.

Exclusion criteria

Exclusion Criteria:

  1. Secondary scoliosis caused by identifiable causes such as spinal trauma or prior spinal surgery.
  2. severe functional impairment of heart, liver, or kidney organ function, defined as grade 3 or higher organ dysfunction according to version 5.0.
  3. Malignant tumours, diseases, or other critical systemic illnesses that may interfere with trial outcomes.
  4. Severe cognitive or psychiatric conditions, including diagnosed intellectual disability, psychotic disorders, or major depressive disorder under active psychiatric intervention, that prevent obtaining valid assent or completing study assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Active comparator
    Routine Guideline-Based Conservative Care

    Control participants will receive routine clinician-directed conservative management in accordance with the 2016 SOSORT guidelines, including observation (follow-up every 3-8 months), physiotherapeutic scoliosis-specific exercises (PSSE, 2-7 sessions per week), specialized inpatient rehabilitation (SIR, a 4-week intensive program of 1 h/day, 5 days/week), and bracing (nighttime rigid bracing 8 h/day; part-time rigid bracing 15 h/day; full-time rigid bracing 20 h/day) as clinically indicated. Care is delivered through routine outpatient visits, paper-based education materials, and clinic-driven follow-up reminders via telephone or SMS. Participants in this arm have no access to the digital health management platform.

    Other: Routine Guideline-Based Conservative Care

  • Experimental
    Platform-Supported Individualized Conservative Care

    Intervention participants will receive individualized conservative management supported by the comprehensive digital health management platform and supervised by licensed clinicians. The same guideline-based treatment options as the control group are available (observation, PSSE, specialized inpatient rehabilitation, and bracing), with treatment selection rules strictly following the 2016 SOSORT guidelines. The platform generates decision-support recommendations based on clinical characteristics, radiographic findings, and lifestyle-related risk factors; all platform-generated suggestions must be manually reviewed, adjusted, and formally approved by a licensed clinician before implementation. The platform provides treatment reminders, standardized health education, follow-up scheduling, and secure cross-party communication linking participants, families, schools, and healthcare providers (home-school-hospital collaborative care model).

    Behavioral: Clinician-Supervised, Platform-Assisted Conservative Management

Interventions

  • OtherRoutine Guideline-Based Conservative Care

    Routine conservative management according to the 2016 SOSORT guidelines, comprising observation, physiotherapeutic scoliosis-specific exercises, specialized inpatient rehabilitation, and bracing as clinically indicated. Delivered through routine outpatient consultations; participants have no access to the digital health management platform.

  • BehavioralClinician-Supervised, Platform-Assisted Conservative Management

    Individualized conservative management supported by the comprehensive digital health management platform. The platform generates decision-support recommendations for observation, PSSE, specialized inpatient rehabilitation, or bracing, which must be reviewed, modified as needed, and formally approved by licensed clinicians before implementation. Platform functions include treatment reminders, standardized health education, follow-up scheduling, and home-school-hospital communication. The platform serves solely as a clinical decision-support tool and cannot generate automatic prescriptions or override clinical judgement.

06

What researchers measure

Primary outcomes

  1. Change in Cobb Angle

    Change in Cobb angle from baseline to the 4-month endpoint (baseline Cobb angle minus 4-month Cobb angle; positive value represents curve improvement). Cobb angle will be measured on standing posteroanterior full-spine radiographs by two independent outcome assessors blinded to group allocation, following SRS measurement protocols; a third senior spine specialist arbitrates when disagreement exceeds 3 degrees. Patients wearing braces must remove the brace for at least 24 hours before radiography.

    Time frame: Baseline and Month 4 (primary endpoint)

Secondary outcomes

  1. Treatment Adherence

    For participants prescribed PSSE: exercise adherence = number of completed prescribed PSSE sessions / total number of prescribed sessions x 100%. For participants prescribed bracing: brace-wear adherence = actual wear-time / prescribed daily wear-time x 100%. For participants under observation-only, adherence is coded as not-applicable. Identical definitions and assessment intervals are used in both groups.

    Time frame: Throughout the 4-month intervention period

  2. Mental Health Status (Hamilton Depression Rating Scale-17)

    Depression status will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). Trained research investigators will perform face-to-face clinician-rated interviews adapted for adolescent participants.

    Time frame: Baseline, Month 4, Month 8, and Month 12

  3. Direct Out-of-Pocket Medical Expenditure

    Cumulative direct out-of-pocket medical expenses related to scoliosis management will be recorded from the family/guardian societal perspective.

    Time frame: Month 4 and Month 12

  4. Participant and Guardian Satisfaction

    Participant and guardian satisfaction will be evaluated using a previously validated custom standardized satisfaction questionnaire (provided within the supplementary material).

    Time frame: Month 4 and Month 12

  5. Safety Outcomes (Adverse Events)

    Adverse events and serious adverse events will be recorded and graded according to CTCAE version 5.0. Serious adverse events will be reported to the ethics committee; participants experiencing SAEs do not automatically withdraw from the trial.

    Time frame: Baseline, Month 4, Month 8, and Month 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

Of 224 non-industry interventional studies with no phase under Scoliosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 58. This study's planned 20 months is close to that.

Counting every sponsor, half of 234 studies reached it within 22 months; a quarter within 8 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Aug 2025 → Mar 2025 and primary completion Dec 2025 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Mar 18, 2024
StartActual
Mar 26, 2025was Aug 2025
Primary completionEst.
Nov 30, 2026was Dec 2025
CompletionEst.
Dec 31, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • the Affiliated Zhejiang Provincial People's Hospital to Hangzhou Medical College · Hangzhou, China
Show 1 removed
  • the Affiliated Zhejiang Provincial People's Hospital to Hangzhou Medical College. · Hangzhou, China
Oct 27, 2026
Start date
Aug 1, 2025→Mar 26, 2025
Oct 27, 2026
Primary completion
Dec 1, 2025→Nov 30, 2026
Oct 27, 2026
Study completion
Dec 1, 2026→Dec 31, 2026
Oct 27, 2026
Eligibility
Minimum age 3 Years→12 Years; Maximum age 18 Years→16 Years; Criteria largely rewritten (13 changes)
What changed in the criteria
Inclusion criteria
  • EditedTheConfirmed diagnosis of mild-to-moderate and mild Adolescent Idiopathic Scoliosis (AIS), with a Cobb angle measuringof 10 degrees or greater and less than 45°; degrees.
  • RemovedThe age range of 12 to 16 years old;
  • RemovedParticipants are required to have no history of mental illness, possess normal communication skills, and be proficient in reading and writing;
  • RemovedSigned informed consent by the patient or their family.
  • AddedAge 12 to 16 years, targeting adolescents in the active pubertal growth phase, in whom conservative management (PSSE and bracing) is clinically prioritized.
  • AddedSufficient cognitive and communicative ability to understand the study procedures and use the platform.
  • AddedVoluntary participation confirmed by signed guardian informed consent and adolescent participant assent.
  • AddedParticipants with prior conservative treatment (PSSE or bracing) are eligible provided the treatment regimen has been stable for at least 3 months prior to baseline assessment.
Exclusion criteria
  • RemovedPatients who fulfill any of the following conditions will be excluded a clear history of inducement, such as diseases caused by trauma, surgery, cognitive impairment, severe dysfunction of heart, liver, kidney and other organs, and malignant tumors, immune diseases and other malignant diseases.
  • AddedSecondary scoliosis caused by identifiable causes such as spinal trauma or prior spinal surgery.
  • AddedClinically significant severe functional impairment of heart, liver, or kidney organ function, defined as grade 3 or higher organ dysfunction according to CTCAE version 5.0.
  • AddedMalignant tumours, autoimmune diseases, or other critical systemic illnesses that may interfere with trial outcomes.
  • AddedSevere cognitive or psychiatric conditions, including diagnosed intellectual disability, psychotic disorders, or major depressive disorder under active psychiatric intervention, that prevent obtaining valid assent or completing study assessments.
Oct 27, 2026
Interventions
Added Routine Guideline-Based Conservative Care·Behavioral: Clinician-Supervised, Platform-Assisted Conservative Management; removed Procedure: Conventional treatment·Behavioral: intervention treatment. Arms added: Routine Guideline-Based Conservative Care·Platform-Supported Individualized Conservative Care; arms removed: control·intervention
Oct 27, 2026
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedChange in Cobb AngleTime frame: Baseline and Month 4 (primary endpoint)
  • RemovedNumber of Cobb anglesTime frame: 4 months before the intervention and 4 months after the intervention
  • RemovedAccuracy of new screening modalitiesTime frame: 4 months before and after the intervention, 4 months after the end of the intervention, and 8 months after the end of the intervention
  • RemovedHamilton Depression VolumeTime frame: 4 months before and after the intervention, 4 months after the end of the intervention, and 8 months after the end of the intervention
Oct 27, 2026
Secondary outcomes
5 added
What changed in the outcomes
  • AddedTreatment AdherenceTime frame: Throughout the 4-month intervention period
  • AddedMental Health Status (Hamilton Depression Rating Scale-17)Time frame: Baseline, Month 4, Month 8, and Month 12
  • AddedDirect Out-of-Pocket Medical ExpenditureTime frame: Month 4 and Month 12
  • AddedParticipant and Guardian SatisfactionTime frame: Month 4 and Month 12
  • AddedSafety Outcomes (Adverse Events)Time frame: Baseline, Month 4, Month 8, and Month 12
Oct 27, 2026
Contact
Study contact changed: l•••@163.com · •••3240→l•••@163.com · •••3240. See the current contact
Oct 27, 2026
Title
Personalized Prevention and Treatment Strategies for Adolescent Idiopathic Scoliosis Via a Comprehensive Health Management Platform→Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    1 site added, 1 site removed
    Show site
    • the Affiliated Zhejiang Provincial People's Hospital to Hangzhou Medical College · Hangzhou, China
    Show 1 removed
    • the Affiliated Zhejiang Provincial People's Hospital to Hangzhou Medical College. · Hangzhou, China
    Start date Aug 1, 2025→Mar 26, 2025
    Primary completion Dec 1, 2025→Nov 30, 2026
    Study completion Dec 1, 2026→Dec 31, 2026
    Eligibility Minimum age 3 Years→12 Years; Maximum age 18 Years→16 Years; Criteria largely rewritten (13 changes)
    What changed in the criteria
    Inclusion criteria
    • EditedTheConfirmed diagnosis of mild-to-moderate and mild Adolescent Idiopathic Scoliosis (AIS), with a Cobb angle measuringof 10 degrees or greater and less than 45°; degrees.
    • RemovedThe age range of 12 to 16 years old;
    • RemovedParticipants are required to have no history of mental illness, possess normal communication skills, and be proficient in reading and writing;
    • RemovedSigned informed consent by the patient or their family.
    • AddedAge 12 to 16 years, targeting adolescents in the active pubertal growth phase, in whom conservative management (PSSE and bracing) is clinically prioritized.
    • AddedSufficient cognitive and communicative ability to understand the study procedures and use the platform.
    • AddedVoluntary participation confirmed by signed guardian informed consent and adolescent participant assent.
    • AddedParticipants with prior conservative treatment (PSSE or bracing) are eligible provided the treatment regimen has been stable for at least 3 months prior to baseline assessment.
    Exclusion criteria
    • RemovedPatients who fulfill any of the following conditions will be excluded a clear history of inducement, such as diseases caused by trauma, surgery, cognitive impairment, severe dysfunction of heart, liver, kidney and other organs, and malignant tumors, immune diseases and other malignant diseases.
    • AddedSecondary scoliosis caused by identifiable causes such as spinal trauma or prior spinal surgery.
    • AddedClinically significant severe functional impairment of heart, liver, or kidney organ function, defined as grade 3 or higher organ dysfunction according to CTCAE version 5.0.
    • AddedMalignant tumours, autoimmune diseases, or other critical systemic illnesses that may interfere with trial outcomes.
    • AddedSevere cognitive or psychiatric conditions, including diagnosed intellectual disability, psychotic disorders, or major depressive disorder under active psychiatric intervention, that prevent obtaining valid assent or completing study assessments.
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedChange in Cobb AngleTime frame: Baseline and Month 4 (primary endpoint)
    • RemovedNumber of Cobb anglesTime frame: 4 months before the intervention and 4 months after the intervention
    • RemovedAccuracy of new screening modalitiesTime frame: 4 months before and after the intervention, 4 months after the end of the intervention, and 8 months after the end of the intervention
    • RemovedHamilton Depression VolumeTime frame: 4 months before and after the intervention, 4 months after the end of the intervention, and 8 months after the end of the intervention
    Secondary outcomes 5 added
    What changed in the outcomes
    • AddedTreatment AdherenceTime frame: Throughout the 4-month intervention period
    • AddedMental Health Status (Hamilton Depression Rating Scale-17)Time frame: Baseline, Month 4, Month 8, and Month 12
    • AddedDirect Out-of-Pocket Medical ExpenditureTime frame: Month 4 and Month 12
    • AddedParticipant and Guardian SatisfactionTime frame: Month 4 and Month 12
    • AddedSafety Outcomes (Adverse Events)Time frame: Baseline, Month 4, Month 8, and Month 12
    Interventions Added Routine Guideline-Based Conservative Care·Behavioral: Clinician-Supervised, Platform-Assisted Conservative Management; removed Procedure: Conventional treatment·Behavioral: intervention treatment. Arms added: Routine Guideline-Based Conservative Care·Platform-Supported Individualized Conservative Care; arms removed: control·intervention
    Contact Study contact changed: l•••@163.com · •••3240→l•••@163.com · •••3240. See the current contact
    Title Personalized Prevention and Treatment Strategies for Adolescent Idiopathic Scoliosis Via a Comprehensive Health Management Platform→Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
    + 5 other changes: verification date, description, conditions, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06314594
Lead sponsor
Hangzhou Medical College
Responsible party
Sponsor
First posted
Mar 18, 2024
Start date
Mar 26, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 27, 2026

Study contacts

Xinyun LI, Doctor
Contact
lxyjasmine2010@163.com
8618069783240
Xinyun Li, doctor
principal investigator · Hangzhou Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion